{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:28:32Z","timestamp":1793978912252,"version":"4.8.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["T2225002"],"award-info":[{"award-number":["T2225002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["E404005"],"award-info":[{"award-number":["E404005"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017291","name":"Zhongshan Science and Technology Bureau","doi-asserted-by":"publisher","award":["CXTD2023009"],"award-info":[{"award-number":["CXTD2023009"]}],"id":[{"id":"10.13039\/501100017291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017291","name":"Zhongshan Science and Technology Bureau","doi-asserted-by":"publisher","award":["CXTD2022013"],"award-info":[{"award-number":["CXTD2022013"]}],"id":[{"id":"10.13039\/501100017291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004739","name":"Youth Innovation Promotion Association of the Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["2023296"],"award-info":[{"award-number":["2023296"]}],"id":[{"id":"10.13039\/501100004739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119274","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:53:25Z","timestamp":1787640805000},"page":"119274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development of potent and selective ENPP1 inhibitors based on imidazo[1,2-a]pyrazine and pyrazine scaffolds for cancer immunotherapy"],"prefix":"10.1016","volume":"319","author":[{"given":"Zhiyue","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiping","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanru","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6984-7663","authenticated-orcid":false,"given":"Bozhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2505-3529","authenticated-orcid":false,"given":"Huiying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-9149","authenticated-orcid":false,"given":"Xiaowei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119274_bib1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119274_bib2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12943-019-1087-y","article-title":"STING: a master regulator in the cancer-immunity cycle","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119274_bib3","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/j.apsb.2020.03.001","article-title":"Small molecules targeting the innate immune cGAS-STING-TBK1 signaling pathway","volume":"10","author":"Ding","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119274_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00018-024-05191-6","article-title":"cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors","volume":"81","author":"Li","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2026.119274_bib5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3389\/fonc.2020.00896","article-title":"Activation of STING by cGAMP regulates MDSCs to suppress tumor metastasis via reversing epithelial-mesenchymal transition","volume":"10","author":"Cheng","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119274_bib6","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1126\/science.1229963","article-title":"Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA","volume":"339","author":"Wu","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119274_bib7","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.celrep.2013.05.009","article-title":"The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING","volume":"3","author":"Diner","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.119274_bib8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.immuni.2018.09.016","article-title":"Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response","volume":"49","author":"Marcus","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2026.119274_bib9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","article-title":"Molecular mechanisms and cellular functions of cGAS-STING signalling","volume":"21","author":"Hopfner","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119274_bib10","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","article-title":"The cGAS-STING pathway and cancer","volume":"3","author":"Samson","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ejmech.2026.119274_bib11","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nchembio.1661","article-title":"Hydrolysis of 2\u20193\u2019-cGAMP by ENPP1 and design of nonhydrolyzable analogs","volume":"10","author":"Li","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119274_bib12","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2119189119","article-title":"ENPP1's regulation of extracellular cGAMP is a ubiquitous mechanism of attenuating STING signaling","volume":"119","author":"Carozza","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2026.119274_bib13","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1038\/s41467-018-06922-7","article-title":"Structural insights into cGAMP degradation by ecto-nucleotide pyrophosphatase phosphodiesterase 1","volume":"9","author":"Kato","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119274_bib14","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/2159-8290.CD-20-0387","article-title":"Metastasis and immune evasion from extracellular cGAMP hydrolysis","volume":"11","author":"Li","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119274_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00441-002-0651-7","article-title":"Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion","volume":"310","author":"Grobben","year":"2002","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.ejmech.2026.119274_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066752","article-title":"Enpp1: a potential facilitator of breast cancer bone metastasis","volume":"8","author":"Lau","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119274_bib17","doi-asserted-by":"crossref","first-page":"7318","DOI":"10.1038\/ncomms8318","article-title":"Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1","volume":"6","author":"Takahashi","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119274_bib18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.clineuro.2010.11.018","article-title":"The expression of ecto-nucleotide pyrophosphatase\/phosphodiesterase 1 (E-NPP1) is correlated with astrocytic tumor grade","volume":"113","author":"Aerts","year":"2011","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.ejmech.2026.119274_bib19","first-page":"134","article-title":"Dysregulated ENPP1 increases the malignancy of human lung cancer by inducing epithelial-mesenchymal transition phenotypes and stem cell features","volume":"9","author":"Hu","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119274_bib20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning cold into hot: firing up the tumor microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejmech.2026.119274_bib21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/13543776.2022.2058874","article-title":"Nucleotide pyrophosphatase\/phosphodiesterases (NPPs) including NPP1 and NPP2\/ATX as important drug targets: a patent review (2015-2020)","volume":"32","author":"Bano","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.119274_bib22","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.3390\/molecules24224192","article-title":"ENPP1, an old enzyme with new functions, and small molecule inhibitors-a STING in the tale of ENPP1","volume":"24","author":"Onyedibe","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119274_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113339","article-title":"Synthesis, biological evaluation, and docking studies of novel pyrrolo[2,3-b]pyridine derivatives as both ectonucleotide pyrophosphatase\/phosphodiesterase inhibitors and antiproliferative agents","volume":"217","author":"Ullah","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119274_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128947","article-title":"Discovery of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one and 3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one derivatives as novel ENPP1 inhibitors","volume":"75","author":"Jung","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119274_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116211","article-title":"Ecto-nucleotide pyrophosphatase\/phosphodiesterase 1 inhibitors: research progress and prospects","volume":"267","author":"Guan","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119274_bib26","doi-asserted-by":"crossref","first-page":"15141","DOI":"10.1021\/acs.jmedchem.3c01061","article-title":"Discovery of orally bioavailable phthalazinone analogues as an ENPP1 inhibitor for STING-mediated cancer immunotherapy","volume":"66","author":"Cho","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119274_bib27","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1021\/acs.jmedchem.3c02288","article-title":"Discovery of pyrido[2,3-d]pyrimidin-7-one derivatives as highly potent and efficacious ectonucleotide pyrophosphatase\/phosphodiesterase 1 (ENPP1) inhibitors for cancer treatment","volume":"67","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119274_bib28","doi-asserted-by":"crossref","first-page":"18317","DOI":"10.1021\/acs.jmedchem.4c01634","article-title":"Discovery of imidazo[1,2-a]pyrazine derivatives as potent ENPP1 inhibitors","volume":"67","author":"Zhan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119274_bib29","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1021\/acs.jmedchem.4c03207","article-title":"Design, synthesis, and pharmacological evaluation of quinazoline and quinoline derivatives as potent ENPP1 inhibitors for cancer immunotherapy","volume":"68","author":"He","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119274_bib30","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1038\/s41467-025-59874-0","article-title":"Oral ENPP1 inhibitor designed using generative AI as next generation STING modulator for solid tumors","volume":"16","author":"Pu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119274_bib31","doi-asserted-by":"crossref","first-page":"16059","DOI":"10.1021\/acs.jmedchem.5c01021","article-title":"Identification of 5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one derivatives as ENPP1 inhibitors for STING pathway-mediated immunotherapy","volume":"68","author":"Ji","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119274_bib32","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT161","article-title":"Abstract CT161: first-in-human study of ENPP1 inhibitor, SR-8541A, for the treatment of solid tumors","volume":"84","author":"Weston","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119274_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e14550","article-title":"First-in-human experience using RBS2418, an oral ENPP1 inhibitor within an expanded access protocol in combination with pembrolizumab in a patient with metastatic adrenal cancer","volume":"40","author":"Csiki","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119274_bib34","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-29223-1","article-title":"873 ISM5939, a novel, potent, orally available, selective ENPP1 inhibitor enhances the anti-tumor effects of immune checkpoint inhibitors in syngeneic murine cancer models","volume":"11","author":"Chen","year":"2023","journal-title":"J. Immuno. Ther. Cancer"},{"key":"10.1016\/j.ejmech.2026.119274_bib35","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-21-LBA009","article-title":"Abstract LBA009: orally available ENPP1 inhibitor, TXN10128, restores STING activation in tumor microenvironment and confers anti-tumor responses in combination with immune checkpoint blockade","volume":"20","author":"Kim","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119274_bib36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1538-7445.AM2023-577","article-title":"Abstract 577: ENPP1 inhibitor ZX-8177 in combination with chemotherapy or radiation exhibits synergistic anti-tumor effects via STING-mediated response","volume":"83","author":"Qin","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119274_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101526","article-title":"Structure and function of the ecto-nucleotide pyrophosphatase\/phosphodiesterase (ENPP) family: tidying up diversity","volume":"298","author":"Borza","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119274_bib38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.chom.2015.07.001","article-title":"STING activation by translocation from the ER is associated with infection and autoinflammatory disease","volume":"18","author":"Dobbs","year":"2015","journal-title":"Cell Host Microbe"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:07:01Z","timestamp":1793977621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":38,"alternative-id":["S0223523426007191"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119274","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of potent and selective ENPP1 inhibitors based on imidazo[1,2-a]pyrazine and pyrazine scaffolds for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119274","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119274"}}